SPOTLIGHT -
Dr Miller is Medical Director, Brain Health, Exeter, New Hampshire; Editor in Chief, Psychiatric Times; Staff Psychiatrist, Seacoast Mental Health Center, Exeter; and Consulting Psychiatrist, Insight Meditation Society, Barre, Massachusetts.
Complex PTSD: A Necessary DSM Addition
There is still no formal or professional recognition of complex PTSD as a very different disorder than what DSM-5-TR describes for PTSD.
Meditation Is Not What You Think
The Harms and Consequences of Untreated PTSD
John J. Miller, MD, discusses the risks of untreated PTSD and the importance of implementing more therapeutic tools into treatment paradigms.
Do No Harm: Providing Guardrails for Effective PTSD Treatments
Addressing the importance of safe treatments for PTSD, Dr John Miller discusses adverse effect management practices and the role of REMS protocols.
Unmet Needs and the PTSD Treatment Pipeline
Focusing on the future of PTSD treatment, Dr John Miller outlines how novel treatments can address current challenges and unmet needs in the therapeutic landscape.
The Challenges of PTSD Symptom Clusters
John J. Miller, MD, provides an overview of the symptom clusters of PTSD and treatments that are being looked at to improve patient care.
MDMA-Assisted Therapy: Providing the Brain With a Necessary Boost
The Psychiatric Times editor-in-chief shares perspectives on how a novel treatment, MDMA-assisted therapy, can potentially change the treatment landscape and improve patients’ lives.
The Evolution of PTSD Diagnosis and Treatment
John J. Miller, MD, discusses how the diagnosis and treatment of posttraumatic stress disorder (PTSD) has evolved over time.
We’ve Only Just Begun…
Psychiatry is such a young field attempting to improve functioning and quality of life for so many diverse and complex brain disorders that it should be no surprise that our treatment outcomes spread across the spectrum from much improved to progressive decline.
Medication-Assisted Psychotherapy: Moving Forward
The FDA did not vote to deny approval of MDMA-assisted psychotherapy on June 4, 2024, contrary to all the buzz in the media saying they did. Learn more here.
Insights and Explorations
In this Special Report, get the latest from the American Psychiatric Association Annual Meeting!
A Curious Juxtaposition
The Psychiatric Times Editor-in-Chief discusses the clinical uses and casual prescribing of ketamine for the treatment of psychiatric disorders.
Reviewing the FDA Advisory Committee Decision on MDMA
Psychiatric Times Editor-in-Chief shares his thoughts on the FDA Psychopharmacologic Drugs Advisory Committee decision for MDMA.
Histamine: Psychiatry’s Neglected Monoamine
Understanding the heterogeneity and complexities of the histamine monoamine system.
Pharmacogenomics: Sticking to the Evidence Base
Pharmacogenomics at the 2024 APA Annual Meeting.
Bias in Record Keeping: A Real Life Example
Biases can be apparent in case notes. Psychiatric Times Editor-in-Chief sat down with us at the 2024 APA Annual Meeting to share more.
Long-Acting Injectable vs Oral Antipsychotics: Part 2 of a Conversation With Peter J. Weiden, MD
Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 2 of their conversation.
Long-Acting Injectables: Part 1 of a Conversation With Peter J. Weiden, MD
Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 1 of their conversation.
Lithium Undervalued? A Conversation With Jonathan M. Meyer, MD
Jonathan M. Meyer, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.
An Artisanal Approach to Care: A Conversation with Joseph F. Goldberg, MD
Joseph F. Goldberg, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.
Suicide
Suicide is a word that conjures a wide range of intense emotions.
Exploring the STAR*D Controversy
STAR*D trial is one of the most important foundational studies in psychiatry to guide the treatment of unipolar major depression. Get ready to explore a dialogue between the original STAR*D authors and a group of authors who call STAR*D into question.
Mass Shootings’ Relationship to Mental Illness
If all violence in the US that is due to mental disorders could be eliminated, 95% to 97% of violent behavior would remain.
Medication Pipeline: Antidepressants and ADHD Rx
Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.
Medication Pipeline: Schizophrenia and PTSD
Here's an update on which medications are on the horizon for the treatment of schizophrenia and PTSD.
STAR*D Dethroned?
Since 2006, STAR*D stands out as an icon guiding treatment decisions of major depressive disorder. But what if it is broken?
Gabapentinoids: A Deeper Look
"During the past 5 years has gabapentin retained its position as one of the top 10 drugs prescribed in the United States."
Deep Dive on Dementia at the 2023 Psychiatric Times World CME Conference
Don't miss the the 2023 Psychiatric Times World CME conference, where our Editor in Chief will present on the 14 different types of dementia!
Updates on Schizophrenia at the 2023 Psychiatric Times World CME Conference
Don't miss updates on schizophrenia at our conference, beginning at 3:10PM EST!
Why You Should Attend the 2023 Psychiatric Times World CME Conference
Our Editor in Chief explains why you should attend our conference!